Privium Fund Management B.V. Has $3.43 Million Holdings in Moderna, Inc. (NASDAQ:MRNA)

Privium Fund Management B.V. increased its position in Moderna, Inc. (NASDAQ:MRNA) by 103.7% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 82,476 shares of the company’s stock after purchasing an additional 41,994 shares during the period. Moderna comprises about 0.8% of Privium Fund Management B.V.’s investment portfolio, making the stock its 23rd biggest holding. Privium Fund Management B.V.’s holdings in Moderna were worth $3,429,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Wilmington Savings Fund Society FSB boosted its position in shares of Moderna by 295.0% in the fourth quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock worth $33,000 after buying an additional 587 shares during the period. Venturi Wealth Management LLC lifted its stake in Moderna by 286.2% in the 4th quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock worth $37,000 after acquiring an additional 664 shares in the last quarter. Compass Planning Associates Inc acquired a new stake in Moderna during the 4th quarter worth about $37,000. Larson Financial Group LLC grew its stake in Moderna by 53.5% during the 3rd quarter. Larson Financial Group LLC now owns 910 shares of the company’s stock valued at $61,000 after acquiring an additional 317 shares in the last quarter. Finally, MassMutual Private Wealth & Trust FSB increased its holdings in shares of Moderna by 58.2% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company’s stock valued at $44,000 after purchasing an additional 389 shares during the period. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently commented on MRNA. Evercore ISI set a $50.00 price target on shares of Moderna in a report on Friday, February 14th. Morgan Stanley decreased their target price on shares of Moderna from $70.00 to $38.00 and set an “equal weight” rating for the company in a research note on Wednesday, January 15th. Berenberg Bank upped their price target on shares of Moderna from $33.00 to $42.00 and gave the stock a “hold” rating in a research note on Thursday, January 16th. Bank of America reduced their price objective on Moderna from $41.00 to $34.00 and set an “underperform” rating for the company in a research report on Tuesday, February 11th. Finally, Leerink Partners dropped their target price on Moderna from $31.00 to $27.00 and set an “underweight” rating on the stock in a research report on Thursday, January 16th. Four investment analysts have rated the stock with a sell rating, sixteen have issued a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Moderna has an average rating of “Hold” and an average target price of $59.60.

Moderna Trading Down 2.6 %

NASDAQ:MRNA opened at $33.81 on Wednesday. The firm has a market capitalization of $13.04 billion, a PE ratio of -3.64 and a beta of 1.86. Moderna, Inc. has a 1 year low of $29.25 and a 1 year high of $170.47. The firm’s fifty day simple moving average is $35.51 and its 200 day simple moving average is $46.55.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.